Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:administrativeDivision |
infusion
every 2 weeks |
| gptkbp:barrelLength |
high
|
| gptkbp:clinicalTrials |
gptkb:Xencor,_Inc.
Phase 1 multiple sites NCTXXXXXXX |
| gptkbp:collaborations |
various research institutions
|
| gptkbp:community_service |
overall survival
progression-free survival |
| gptkbp:contraindication |
fatigue
nausea hepatitis diarrhea rash hypothyroidism neuropathy pneumonitis colitis nephritis |
| gptkbp:currentStatus |
conducted
|
| gptkbp:developedBy |
gptkb:Xencor
|
| gptkbp:dosageForm |
weight-based dosing
|
| gptkbp:evaluates |
under investigation
|
| gptkbp:firstClaim |
gptkb:melanoma
renal cell carcinoma non-small cell lung cancer |
| gptkbp:formulation |
liquid
|
| gptkbp:hasPopulation |
advanced cancer patients
|
| gptkbp:historicalResearch |
recombinant DNA technology
|
| https://www.w3.org/2000/01/rdf-schema#label |
XmAb18098
|
| gptkbp:impact |
T cells
|
| gptkbp:patentAssignee |
gptkb:Xencor,_Inc.
|
| gptkbp:productionCompany |
early clinical trials
|
| gptkbp:purpose |
cancer immunotherapy
|
| gptkbp:regulatoryCompliance |
investigational new drug
|
| gptkbp:relatedTo |
immune system
|
| gptkbp:releaseYear |
2010
|
| gptkbp:research |
biopharmaceutical research
pharmaceutical grants |
| gptkbp:research_areas |
monoclonal antibodies
immunotherapy |
| gptkbp:researchFocus |
oncology
|
| gptkbp:researchInterest |
academic institutions
|
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
monitored in trials
|
| gptkbp:sideEffect |
immune-related adverse events
|
| gptkbp:status |
in development
|
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
T lymphocytes
PD-1 PD-1/PD-L1 pathway |
| gptkbp:triggerType |
immune checkpoint inhibition
blocks PD-1 receptor |
| gptkbp:usedFor |
cancer treatment
|